**Specifications Table**SubjectHematologySpecific subject areaPharmacokinetics of a new plasma-derived FIX concentrateType of dataTables\
GraphsHow data were acquiredPharmacokinetic data, FIX:C/times, at enrolment and after six months of treatment, (on-demand five patients, prophylaxis nine patients) have been collected at the end of a regulatory, clinical trial of new Kedrion FIX concentrate (See Supplementary data)\
Instruments: WinNonlin 7.0, Phoenix, Pharsight Corp, California, USA: Non-compartment Analysis (NCA) and Two Compartment Model (TCM or 2CP model)Data formatRaw data Analyzed: FIX:C IU/dL,\
Lambda_z 1/hrs, HL_Lambda_z hrs, Cmax/Dose IU/dL/IU/kg, AUC U\*h/dL, AUMC U\*h2/dL, Vd dL/kg, Cl dL/h/kg, MRT hrs, Alpha 1/hrs, Alpha_HL hrs, Beta_HL hrs, Vss dL/kgParameters for data collectionHaemopilia B severe or moderately severe patients underwent a single dose Kedrion FIX PK after 3-4 days wash out. FIX assay has been centralized in a single LaboratoryDescription of data collectionThe data were collected using a Case Report Form, according to the protocol approved, see Eudract-Code 2005-006186-14Data source locationInstitution: Kedrion Biopharma\
City/Town/Region: Barga (Lucca)\
Country: Italy\
Latitude and longitude (and GPS coordinates, if possible) for collected samples/data: Not available\
Primary data sources: Clinical Study Report KB037, 21/12/2001Data accessibilityThe source data, individual single-dose PK I and II, are hosted with the article as supplementary data.Related research articleCastaman G., Borchiellini A., Santagostino E., Radossi P., Aksu S., Yilmaz M., Serban M, Uscatescu V, Truica C, Fasulo MR, Mancuso ME, Paladino E.,Valpreda A., Guarnieri C., Macchia R., Scarpellini M., Mathew P., and Morfini M.\
Non-Compartment and Compartmental Pharmacokinetics, Efficacy, and Safety of Kedrion FIX concentrate Eur J Pharm Sci. 2020 Jul 23:105485. doi: 10.1016/j.ejps.2020.105485. Online ahead of print.PMID: [32712218](pmid:32712218){#interref0001}

**Value of the Data**•The new Kedrion FIX concentrate was submitted to three different viral inactivation steps to improve the safety of a pdFIX product; thus, it is essential to evaluate its safety, efficacy, and pharmacokinetics•Physicians can use this information to better serve the needs of patients with FIX deficiency. Haemophilia B patients can achieve therapeutic levels of FIX from a safer and cheaper FIX concentrate•The accurate PK data according to TCM may be useful to tailor the dosing frequency of prophylaxis, according to individual clearance of the concentrate (personalized prophylaxis)•The improvement of PK parameters observed in haemophilia B patients who undergo prophylaxis might convince them to switch from on-demand to prophylaxis, thus decreasing joint arthropathy, improving quality of life for the patient, and thus improving productivity for society•Compared to the new and expensive extended half-life rFIX concentrates, Kedrion FIX may be cost/effectiveFig. 1aPlots of FIX:C decay curve by means of NCA, according to 11 sample points, at enrollment (PK I)Fig 1a:Fig. 1bPlots of FIX:C decay curve by means of NCA, according to 9 sample points, at enrollment (PK I)Fig 1b:Fig. 2aPlots of FIX:C decay curve by means of NCA, according to 11 sample points, at the end of the trial (PK II)Fig 2a:Fig. 2bPlots of FIX:C decay curve by means of NCA, according to 9 sample points, at the end of the trial (PK II)Fig 2b:Fig. 3aPlots of FIX:C decay curve by means of 2CP model, according to 11 sample points, at enrollment (PK I)Fig 3a:Fig. 3bPlots of FIX:C decay curve by means of 2CP model, according to 9 sample points, at enrollment (PK I)Fig 3b:Fig. 4aPlots of FIX:C decay curve by means of 2CP model, according to 11 sample points, at the end of trial (PK II)Fig 4a:Fig. 4bPlots of FIX:C decay curve by means of 2CP model, according to 9 sample points, at the end of trial (PK II)Fig 4b:

1. Data Description {#sec0001}
===================

The raw data of Kedrion FIX concentrate PK performed in 14 haemophilia B patients \[on demand (n = 5) or continuous prophylaxis (n = 9)\], at enrolment in the clinical trial and after six months of treatment, are reported in the supplementary data file (Kedrion FIX PK I data.xls and KedrionFIX PK II data.xls). [Figs. 1a](#fig0001){ref-type="fig"}/[Fig. 1b](#fig0002){ref-type="fig"}, [Fig. 2a](#fig0003){ref-type="fig"}/[2b](#fig0004){ref-type="fig"} shown the plots according to the two, 11 or 9, FIX/time sample point designs of PK I and PK II, using NCA. The different Terminal HLs are shown as the result of the selection of the last best fitting points. [Tables 1a](#tbl0001){ref-type="table"} and [1b](#tbl0002){ref-type="table"} report in detail the parameters of PK I and PK II achieved by NCA, according to a 11 and 9 sample points deseign. [Figs. 3a](#fig0005){ref-type="fig"}/[Fig. 3b](#fig0006){ref-type="fig"}, [Fig. 4a](#fig0007){ref-type="fig"}/[4b](#fig0008){ref-type="fig"} shown the data obtained using TCM again according to the two different, 11 or 9, sample point designs of PK I and PK II. Alpha and Beta HL of each PK are also added to each plot. [Tables 2a](#tbl0003){ref-type="table"} and [2b](#tbl0004){ref-type="table"} report in detail the parameters of PK I and PK II achieved by TCM, according to a 11 or 9 sample points design. The source data, the assays of FIX:C (IU/dL), the bodyweight of the patient, the infused dose of Kedrion FIX (IU/kg), and the post-infusion sample times are reported in the files provided as Supplementary data. The data are reported according to the format required by WinNonlin.Table 1aParameters of PK I and PK II by Non-Compartmental Analysis; as far as the Terminal HL (HL Lambda_Z), two outliers (patients 03 01 and 14 05, bold and in Italics) are present in the outcomes of PK II. Significant improvements of AUC, AUMC, Cl, and MRT were observed at PK IITable 1aNon-Compartmental Analysis (11 post-infusion points)EnrollmentLambda_zHL_Lambda_zCmax_DAUCVdClAUMCMRTNID1/HoursHoursIU/dL/IU/kgU\*h/dLdL/kgdL/h/kgU\*h^2^/dLHours101 010.019136.211.0716251.29170.02473998924.62101 020.017040.831.1913861.34640.02293409124.60102 010.019435.781.3017161.15620.02244238524.70103 010.031222.201.5420820.67270.02104680722.48104 010.019335.981.5422960.83780.01615940825.88109 020.024927.791.5722750.71680.01795775125.38112 010.025627.032.2029250.53730.01387118724.33112 020.013451.691.0316971.52470.02044440026.16114 010.023229.911.2217581.00740.02334253424.20114 020.012455.731.0112222.09850.02612964424.27114 030.013850.151.0914661.94170.02683338322.77114 040.014149.131.4017551.50350.02123915722.32114 050.025027.721.2218010.89230.02234535025.18115 010.023928.980.767062.73760.06551689723.9214Mean0.020237.081.2917651.30460.02464307024.34Median0.019335.881.2217351.22390.02244245924.471 S.D.0.005710.770.355310.62090.0123134721.18Min0.012422.200.767060.53730.01381689722.32Max0.031255.732.2029252.73760.06557118726.16End of the studyLambda_zHL_Lambda_zCmax_DAUCVdClAUMCMRTNID1/HoursHoursIU/dL/IU/kgU\*h/dLdL/kgdL/h/kgU\*h^2^/dLHours101 010.023629.421.1918260.98000.02314556524.95101 020.013451.691.1415861.32840.01784259026.86102 010.016242.701.2617421.30630.02124348624.961*03 010.16554.191.7825520.11820.01965546121.73*104 010.021032.981.4420980.87450.01845222824.90109 020.022131.411.7029220.63410.01407649726.18112 010.018437.631.8630920.69610.01287946525.70112 020.021132.790.9112991.46360.03093372925.96114 010.035919.311.2820550.60140.02165127924.96114 020.018138.381.3217161.16140.02104112223.96114 030.025926.721.2419580.83620.02174788524.46114 040.025227.561.3419790.79630.02004956325.041*14 050.0022321.841.2820971.95950.00426137929.27*115 010.016043.190.559502.51930.04042599227.3514Mean0.030352.841.3119911.09110.02055044625.45Median0.021132.891.2819680.92730.02054872425.001 S.D.0.039678.260.345760.60780.0083146101.74Min0.00224.190.559500.11820.00422599221.73Max0.1655321.841.8630922.51930.04047946529.27Wilcoxon signed-rank testZ-0.91030.7533-0.4394-2.4797-1.6636-2.1030-2.4797-2.2286P0.3600.4500.6600.0130.0970.0360.0130.026Table 1b-- Parameters of PK I and PK II by Non-Compartmental Analysis according to 9 post-infusion FIX/time points; a significant improvement of AUC, AUMC, Cl, and MRT was observed at PK IITable 1bNon-Compartmental Analysis (9 post-infusion points)EnrollmentLambda_zHL_Lambda_zCmax_DAUCVdClAUMCMRTNID1/HoursHoursIU/dL/iu/kgU\*h/dLdL/kgdL/h/kgU\*h^2^/dLHours101 010.024827.901.0716321.04320.02593971024.33101 020.023030.091.1914091.05150.02423456824.53102 010.019136.311.3017211.16680.02234226524.56103 010.030222.931.5421000.70430.02134618521.99104 010.019136.311.5423120.83920.01605959925.78109 020.022930.281.5721830.89340.02045086423.30112 010.025627.062.2028760.54560.01406852423.83112 020.020433.911.0317081.12130.02294404025.79114 010.023129.981.2217681.00440.02324240623.98114 020.018836.941.0111951.64620.03092809723.51114 030.029723.311.0914461.06200.03163229322.33114 040.030522.691.4017250.85190.02603647021.14114 050.023729.201.2217241.02220.02434079123.67115 010.025227.550.767162.59300.06521704523.7914Mean0.024029.601.2917511.11040.02634163323.75Median0.023429.591.2217221.03270.02374152823.811 S.D.0.00404.870.355190.49530.0122127541.31Min0.018822.690.767160.54560.01401704521.14Max0.030536.942.2028762.59300.06526852425.79End of the studyLambda_zHL_Lambda_zCmax_DAUCVz_F\_obsCl_F\_obsAUMCMRTNID1/HoursHoursIU/dL/IU/kgU\*h/dLdL/kgdL/h/kgU\*h^2^/dLHours101 010.023030.191.1918320.99820.02294507024.60101 020.015445.111.1415701.22020.01884151126.44102 010.022930.251.2617490.99860.02294307824.63103 010.061311.311.7825450.31950.01965326520.93104 010.020334.151.4420830.90370.01835107624.53109 020.015544.841.7029820.81060.01257817626.22112 010.023229.901.8630940.58150.01357826525.30112 020.021632.060.9113331.40940.03053437925.79114 010.027125.611.2819730.79610.02154665223.65114 020.018238.001.3217561.13280.02074210623.97114 030.024528.281.2420040.85880.02104855724.24114 040.024128.761.3419820.82260.01984901124.72114 050.015245.531.2821650.92650.01416289029.04115 010.018138.280.5510022.22710.04032711027.0514Mean0.023633.021.3120051.00040.02125008225.08Median0.022331.161.2819780.91510.02024760424.681 S.D.0.01159.150.345730.44040.0071145701.87Min0.015211.310.5510020.31950.01252711020.93Max0.061345.531.8630942.22710.04037826529.04Wilcoxon signed-rank testZ-1.287-1.143-0.439-2.351-1.726-293.000-2.480-2.201p0.1290.1580.6590.0190.8640.0220.0130.028Table 2aOutcomes of TCM at PK I and II, according to a post-infusion FIX/time 11 points. Two patients at PK I and five at PK II showed extremely high and unbelievable parameters due to the very flat disposition of the last part of the decay curveTable 2a:Two Compartment Model (11 points)At enrolmentAlpha_HLAUCBeta_HLCLK10_HLMRTVssNIDhrsU\*h/dLhrsdL/h/kghrshrsdL/kg101 011.58189226.770.027123.4238.291.0379101 027.89185743.270.023125.3054.351.2544102 016.09219136.640.022823.9848.221.10041*03 01\*16.90\>5000\>2000.009050.29\>2004.2810*104 014.99297735.860.016427.3449.490.81101*09 02\*10.76\>10000\>2000.0001\>200\>2003.2759*112 012.24343227.650.013922.1839.090.5447112 023.53215333.530.023928.0747.391.1326114 016.88212331.460.023523.9142.250.9951114 028.13183060.020.026026.4471.701.8661114 034.45162924.440.032719.6733.711.1035114 0412.13236262.090.021223.3660.551.2821114 0512.25284370.900.017632.6481.561.4346115 010.3679724.640.069710.5634.862.428314End of the studyAlpha_HLAUCBeta_HLCLK10_HLMRTVssNIDhrsU\*h/dLHrsdL/h/kghrshrsdL/kg101 010.84214827.250.023923.7339.130.9342101 025.64220542.150.019431.1957.951.1262102 013.33212730.970.023522.8242.961.0097104 010.71239825.790.020323.0737.090.75441*09 02\*16.05\>5000\>2000.0038\>100\>2002.1993*112 0110.27399436.800.013129.2549.270.6436112 020.62158930.010.032421.4042.931.3906114 010.04235925.440.021224.1236.690.77791*14 02\*13.73\>30000\>2000.0015\>200\>2005.1104*1*14 03\*17.57\>30000\>2000.0013\>200\>2006.8169*1*14 04\*14.99\>5000\>2000.009057.46\>2002.5862*1*14 05\*10.54\>150000\>2000.0001\>200\>2002.4700*115 010.34122233.080.045524.3847.552.161013\* Outliers[^1]Table 2bOutcomes of TCM at PK I and II, according to a post-infusion FIX/time 9 points design. No patient shoved outlier outcomes.Table 2b:Two Compartment Model (9 points)At enrollmentIDAlpha_HLAUCAUMCBeta_HLCLK10_HLMRTVsshrsU\*h/dLU\*h^2^/dLhrsdL/h/kgHrshrsdL/kg01 011.6119207484627.260.026723.7738.981.041201 026.8818449470939.580.023225.0851.361.193702 016.41224211338338.760.022324.5650.561.127503 010.9822566807420.960.022220.1030.180.669004 014.92302415273536.570.016127.7650.500.814709 028.07271412659438.120.019722.1946.640.920412 012.54335712907627.300.014221.7538.450.547712 023.42219710635334.230.023428.6248.411.134414 016.8821409155031.890.023424.0942.791.000014 028.0116339629749.740.029223.6058.951.718514 038.3917257102633.600.030920.9641.171.272514 046.9618775833823.390.026618.4831.080.827814 0510.9921289688737.400.023524.4245.531.070015 010.368102874625.060.068510.7235.472.4311Mean5.4621339347233.130.026422.5843.581.1263Median6.6421349550333.910.023423.6844.161.05561S.D.3.21621320867.760.01294.378.250.4705Min0.368102874620.960.014210.7230.180.5477Max10.99335715273549.740.068528.6258.952.4311End of the studyIDAlpha_HLAUCAUMCBeta_HLCLK10_HLMRTVsshrsU\*h/dLU\*h^2^/dLhrsdL/h/kgHrshrsdL/kg01 010.8321518423227.270.023823.7639.160.933601 027.75232915538950.290.018433.0666.721.227802 013.6821699712032.500.023123.2944.781.032603 012.57299610742525.060.016723.1635.850.598304 0111.83280715899547.270.017428.1956.640.984209 020.62328912496126.730.016324.2938.000.619012 0112.76412922488143.220.012630.2454.460.688112 020.6216587440431.350.031022.3344.871.392814 014.27223511581338.630.022423.6151.821.159214 0213.35226012822757.540.021124.3456.751.195914 030.1021687149022.870.024621.5732.980.811514 046.1422048115626.620.022722.5736.820.835114 050.65259112316533.900.019327.1647.540.917515 010.3112215708433.310.045524.3146.742.1258Mean4.68244311459635.470.022525.1346.651.0372Median3.12224711161932.900.021724.0345.800.95891 S.D.4.917084415410.520.00803.329.730.3919Min0.1012215708422.870.012621.5732.980.5983Max13.35412922488157.540.045533.0666.722.1258Wilcoxon signed-rank testZ-0.7219-2.4169-2.1658-0.9730-2.2913-1.9775-1.2241-1.0358p0.4720.0160.0300.3320.0220.0480.2250.298

2. Experimental Design, Materials and Methods {#sec0002}
=============================================

Fourteen severe or moderately severe haemophilia B patients from eight Comprehensive Haemophilia Centres (4 in Italy, 3 in Romania, and 1 in Turkey) were enrolled in a new clinical trial plasma-derived FIX concentrate \[KB037 trial\]. The poor-platelet citrated plasmas have been collected before and after 0.25, 0.5, 1, 3, 9, 24, 32, 48, 50, and 72 of the test dose of Kedrion FIX (11 points), according to a dense sample times design (SSE_ISTH). Fresh frozen plasmas have been frozen, stored at -40°C and shipped in dry ice to the Reference Laboratory of the Haemophilia Centre of Florence, within 30 days from the end of PK I or PKII, respectively. The FIX:C assay has been done by the One Stage clotting assay. For more details, see the previously published report [@bib0001]. The PK data have been analysed by Non-Compartment Analysis (NCA), One and Two Compartment Method (OCM and TCM). We consider only NCA and TCM results, being the diagnostic tests for best fitting in favour of TCM [@bib0002]. A simplified sample design was also used to analyze the PK data, only 9 points, eliminating the 30 and 50 h FIX/time values.
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Supplementary material associated with this article can be found, in the online version, at [doi:10.1016/j.dib.2020.106164](https://doi.org/10.1016/j.dib.2020.106164){#interref0002}.

[^1]: ID = 03 01: An error occurred during curve stripping. Initial estimates cannot be determined for this model
